Arbutus Biopharma Corporation (ABUS)

In our clinical evaluation of the pipeline, the alignment with the FDA on the Phase 2b trial design for imdusiran represents a meaningful operational milestone. Treating chronic hepatitis B with an RNAi therapeutic approach is scientifically sound, though the efficacy data heavily relies on combination therapies. From a protocol standpoint, monitoring viral control persistence and safety signals closely will dictate whether imdusiran can stand out independently or if it remains bound to combination frameworks. We are watching the trial execution closely as a key fundamental catalyst.

On our desk, ABUS has completely transformed its financial narrative following the Moderna settlement. Validating their lipid nanoparticle (LNP) delivery intellectual property not only provided a massive non-dilutive liquidity boost and net profitability, but the recent announcement to repurchase up to $230 million of common shares reinforces management's commitment to returning value. With a P/E ratio around 6.07 and a surging stock price pushing past $5, the market is starting to price in this de-risked balance sheet, though finding an attractive entry point requires discipline.

Watching the technical indicators and retail sentiment on ABUS, the stock recently rallied over 10% on the back of the share buyback announcement and Q2 financial results beating estimates. However, risk management remains paramount. While the balance sheet provides a comfortable runway, ongoing patent litigation against Pfizer/BioNTech introduces binary headline risks. Investors should weigh the solid foundation built by the Moderna settlement against potential volatility stemming from broader litigation outcomes and clinical timeline extensions.

Option volume on ABUS indicates large block hedging by prime desks. Downside asymmetry is expanding.